Background: Since the early 2000s rituximab (RTX) has been thought of as an alternative treatment for steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS)., Objective: This study aimed to determine the effects of RTX treatment on disease outcome and growth in pediatric SSNS and SRNS patients., Materials and Methods: The medical records of pediatric SSNS and SRNS patients that began RTX treatment at the mean age of 10.8 ± 5.1 years between 2009 and 2017 were retrospectively reviewed. Additionally, the effect of RTX on growth was evaluated based on patient height, weight, and BMI z scores., Results: The study included 41 children, of which 21 had SSNS and 20 had SRNS. Mean age at diagnosis of NS was 5.8 ...
<b><i>Background:</i></b> Though rituximab (RTX) is effective for childhood steroid-dependent nephro...
Introduction. There is evidence of the effectiveness of rituximab in treatment of nephrotic syndrome...
Abstract In the past 10 years, many reports have sug-gested that rituximab, a chimeric anti-CD20 mon...
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to...
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to...
Aim: We aimed to evaluate the efficacy of rituximab therapy in children with nephrotic syndromes and...
Objective: To explore the effectiveness and safety of rituximab (RTX) for steroid-dependent or frequ...
Rituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for refractory...
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. A total of ...
BACKGROUND: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy ...
Aim: We aimed to evaluate the efficacy of rituximab therapy in children with nephrotic syndromes and...
Corticosteroid resistant and dependent nephrotic syndrome in children is a challenge and there are s...
Background: Nephrotic syndrome (NS) in children is a disease of glomerular filtration barrier failur...
ObjectivesRituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for ...
Steroid-dependent nephrotic syndrome (SDNS) carries a high risk of toxicity from steroids or steroid...
<b><i>Background:</i></b> Though rituximab (RTX) is effective for childhood steroid-dependent nephro...
Introduction. There is evidence of the effectiveness of rituximab in treatment of nephrotic syndrome...
Abstract In the past 10 years, many reports have sug-gested that rituximab, a chimeric anti-CD20 mon...
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to...
Background/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to...
Aim: We aimed to evaluate the efficacy of rituximab therapy in children with nephrotic syndromes and...
Objective: To explore the effectiveness and safety of rituximab (RTX) for steroid-dependent or frequ...
Rituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for refractory...
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. A total of ...
BACKGROUND: The anti-CD20 monoclonal antibody rituximab (RTX) has been proposed as a rescue therapy ...
Aim: We aimed to evaluate the efficacy of rituximab therapy in children with nephrotic syndromes and...
Corticosteroid resistant and dependent nephrotic syndrome in children is a challenge and there are s...
Background: Nephrotic syndrome (NS) in children is a disease of glomerular filtration barrier failur...
ObjectivesRituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for ...
Steroid-dependent nephrotic syndrome (SDNS) carries a high risk of toxicity from steroids or steroid...
<b><i>Background:</i></b> Though rituximab (RTX) is effective for childhood steroid-dependent nephro...
Introduction. There is evidence of the effectiveness of rituximab in treatment of nephrotic syndrome...
Abstract In the past 10 years, many reports have sug-gested that rituximab, a chimeric anti-CD20 mon...